Navigation Links
Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
Date:10/30/2013

CAMBRIDGE, Mass., Oct. 30, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced results of a global, Phase 2, open-label, randomized study of MM-121 in combination with paclitaxel versus paclitaxel alone in patients with platinum-resistant or platinum-refractory advanced ovarian cancers.

This study did not meet the primary endpoint of progression free survival in the overall population.  The hazard ratio (HR) for progression free survival (PFS) was 1.0 [95% CI 0.74 - 1.4].

Ongoing analysis of a pre-specified set of biomarkers mechanistically linked to ErbB3 signaling identified a potential subpopulation of patients benefiting from MM-121 treatment in combination with paclitaxel. When using a combination of two biomarkers, the hazard ratio for PFS was 0.37 [95% CI 0.2 - 0.8] in the 34% of patients who were biomarker positive. The hazard ratio for PFS in the biomarker negative population was 1.54 [95% CI 1.0 - 2.4].

An overall increase in all grades of gastrointestinal toxicities, including diarrhea (73.6% vs. 42.5%), vomiting (31.4% vs. 18.8%) and other mucosal toxicities such as rhinitis (7.1% vs. 1.3%), epistaxis (23.6% vs. 17.5%), stomatitis (22.1% vs. 10.0%) and mucosal inflammation (22.1% vs. 1.3%), were observed in the combination as compared to paclitaxel alone, the majority of which were mild to moderate in severity. An increase in the pulmonary embolism rate was observed with the combination of MM-121 and paclitaxel (5.0% vs. 1.2%). No enhancement of paclitaxel-related peripheral neuropathy was reported with the combination.

"This unique study design lays the groundwork for future translational studies in ovarian cancer. The rapid enrollment into this study was a testament to the commitment of patients and physicians to advance our knowledge and improve upon available therapies i
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Earnings Releases, Investment Plans, Commencement of Clinical Trials, and FDA Applications Brighten Outlook - Research Report on Bard, Centene, Exact Sciences, Ironwood, and Merrimack
2. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
3. Merrimack Pharmaceuticals Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
4. Merrimack Pharmaceuticals Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
5. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
6. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
7. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
8. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2013 Financial Results On November 5, 2013
9. Cumberland Pharmaceuticals To Announce Third Quarter 2013 Financial Results On November 5, 2013
10. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
11. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015   The New ... injection, Kybella, from internationally acclaimed plastic surgeon, Dr. ... and Drug Administration, is proven to reduce fat deposits ... The active ingredient in Kybella, ... gives plastic surgeons the ability to reshape this area ...
(Date:5/4/2015)... N.J. , May 4, 2015 Thirty-six ... percent seek help. During May – National Hearing Month ... loss could be missing out on the sounds of ... the trees. To ensure that you won,t ... that color our world, Oticon, Inc. offers practical advice: ...
(Date:5/4/2015)... May 4, 2015 PAREXEL International Corporation (NASDAQ: ... the UBS Healthcare Conference on Monday, May 18, 2015, in ... and Chief Financial Officer will be making a presentation on ... A live webcast of the presentation will be available ... in the Upcoming Events portion of the main page, ...
Breaking Medicine Technology:Dr. Rod Rohrich Provides Medical Expertise on Kybella 2Dr. Rod Rohrich Provides Medical Expertise on Kybella 3It's Better Hearing Month 2PAREXEL International to Present at UBS Healthcare Conference 2
... Nov. 11 Shire plc ... biopharmaceutical company, today announced the re-launch of FOCUS ( ... patient support program for adults taking once-daily Vyvanse ... treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded ...
... Deloitte Recap LLC (Recap) has launched "Development ... Series by Deloitte. The series of biopharmaceutical business ... service tailored toward business development, corporate strategy, financial, ... , "Development Optimizer" provides flexible analytical tools for ...
Cached Medicine Technology:Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII 2Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII 3Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII 4Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII 5Deloitte Recap Launches New Solution for Clinical Development 2Deloitte Recap Launches New Solution for Clinical Development 3
(Date:5/4/2015)... York, NY (PRWEB) May 04, 2015 ... specialized insurance programs, announces the expansion of coverage for ... is a leading provider of industry-tailored insurance and proactive ... McNeil & Company, we are dedicated to providing our ... to meet their many evolving needs. We are excited ...
(Date:5/4/2015)... Healthcare Solutions is proud to be a sponsor at ... in Baltimore, MD from May 11 – 13, 2015. ... opportunity for clients to gather to network, attend educational ... to sponsoring the event, TROY Healthcare Solutions will be ... can stop by the TROY booth and see sample ...
(Date:5/4/2015)... 2015 Baptist Medical Center Jacksonville ... Get With The Guidelines®-Stroke Gold Plus Quality Achievement ... The award recognizes the hospital’s commitment and success ... appropriate treatment according to nationally recognized, research-based guidelines ... receive the Gold Plus Quality Achievement Award, hospitals ...
(Date:5/4/2015)... Now in its seventh year, the IPC ... made outstanding contributions to the company, to their facilities ... and post-acute care settings. The five award categories are: ... Year, Advanced Practice Clinician of the Year, Newcomer Provider ... Recipients are selected by IPC’s senior management team. , ...
(Date:5/4/2015)... Los Angeles, CA (PRWEB) May 04, 2015 ... Kevin Sands, is now offering a more comfortable and ... been the restoration of choice for those who have ... patients. Dentures can feel insecure or slip at the ... the patient eats or talks. They can also painfully ...
Breaking Medicine News(10 mins):Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2
... (HealthDay News) -- A certain area of the cerebral cortex ... smoked, finds a new study. The cerebral cortex is ... in reward, impulse control and decision making. German researchers ... smokers and 21 people who never smoked. Using these images, ...
... work night and rotating shifts are almost twice as likely ... day shifts, according to a study by researchers at the ... current issue of the Scandinavian Journal of Work, Environment ... collected as part of Statistics Canada,s Survey of Labour and ...
... HealthDay Reporter , MONDAY, Nov. 1 (HealthDay News) -- There may ... exercise regularly seem to have fewer and milder colds, a new ... catch a cold two to four times a year, and children ... colds sap about $40 billion from the U.S. economy in direct ...
... cancer, one of the most prevalent cancers in women, ... about 40,000 deaths annually. The disease often extends to ... process in which cancer cells invade blood vessels or ... prognosis for patients. Some scientists argue that evidence ...
... Nov. 2 (HealthDay News) -- Extroverts are more vulnerable to ... social activity than after they,ve been alone, researchers have found. ... and 25 introverts (reserved, shy types), aged 18 to 39, ... or a "socially impoverished group." Those in the socially ...
... New York, NY, November 2, 2010An initiative by the ... of proven value less expensive for their employees succeeded ... to a Commonwealth Fund-supported study published in this month,s ... by Niteesh K. Choudhry at Brigham and Women,s Hospital, ...
Cached Medicine News:Health News:Shift work linked to higher risk of work injury: UBC study 2Health News:Exercise May Help Beat the Common Cold 2Health News:Exercise May Help Beat the Common Cold 3Health News:Fox Chase researchers identify risk factors for the spread of breast cancer to lymph nodes 2Health News:Socializing Tied to Sleep Deprivation in Extroverts 2Health News:Eliminating or reducing cost-sharing for high-value prescription drugs improves medication use 2
... Misys Laboratory is a ... that manages specimen data ... specimen tracking to final ... Laboratory is a multi-module ...
...
... IntelliLab is a full-featured ... the processing requirements,of clinical laboratories ... labs. IntelliLab provides order,management, barcode ... control and reporting tools to,ensure ...
... of a cuff for opening the drape ... the cassette. , ,Seamless side construction ... helping to prevent the cassette to be ... ,Adhesive closure provides a secure seal while ...
Medicine Products: